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loci. Donor-specific T-cell cytotoxic crossmatch was strongly
positive, and the kidney was declined. The following month,
she was admitted to the hospital with an episode of staphylococ-
cal line sepsis, treated with a course of vancomycin.
Four months later, a zero-HLA-mismatched kidney was of-
fered to her via the United Network for Organ Sharing (UNOS)
six-antigen-match program. The donor, a resident of Maryland,
was a 61-year-old victim of a cerebrovascular accident and had
a five-year history of treated hypertension. The donor’s serum
creatinine at the time of harvesting was 1.4 mg/dL after reaching
a post-admission peak of 2.2 mg/dL. A renal biopsy performed
at the time of harvesting showed 8 of 50 totally sclerosed glome-
ruli and “minimal” interstitial atrophy. Both standard T-cell
cytotoxic and flow cytometry crossmatching were negative. Both
the donor and recipient were positive for cytomegalovirus anti-
body. After a discussion with the patient and her nephrologistCASE PRESENTATION
regarding the implications of accepting a kidney from a physio-A 48-year-old black woman started hemodialysis six years
logically marginal donor, the transplant was carried out. Theago after a 15-year history of systemic lupus erythematosus,
elapsed time from kidney harvesting to completion of the vas-for which she had received high doses of oral steroids and
cular anastomosis was 32 hours. Evaluation of the donor biopsyazathioprine. Six months after starting dialysis, she was referred
specimen after transplantation showed extensive nephroscl-to the UCLA renal transplant program. She was obese (BMI,
erosis with moderate chronic parenchymal injury (Fig. 1).33 kg/m2) and had a long personal and family history of hyper-
Transplantation was technically uneventful. Urine output intension. Her family history also was notable for type-II diabe-
the first 12 hours varied from 30 to 60 mL/hr despite a low-dosetes; she had no potential living donors. An adenosine cardiolyte
dopamine infusion, saline infusion, and high-dose intravenouscardiac perfusion study was normal. Her name was placed on
furosemide. Immunosuppression was commenced with OKT3the cadaveric transplant list.
in a dose of 5 mg in the operating room and daily for the followingIn the four years that elapsed before she eventually received
10 days. Prednisone, 1000 mg, was given in the operating rooma cadaveric transplant, she was evaluated on an annual basis
and followed by 150 mg on the first day and tapered by 10 mgby the transplant program staff. Additionally, her blood was
daily. A daily infusion of intravenous ganciclovir was given.tested monthly to measure the level of panel-reactive antibod-
On the first postoperative day, a transplant ultrasound withies against T-cells, which varied from 50% to 80% before ab-
power Doppler showed no obstruction and good parenchymalsorption with dithiothreitol (DTT) and 20% to 40% after ab-
flow; diastolic flow was reversed, and the resistive index was 1.1.sorption. She was admitted to the hospital on 11 occasions for
Dialysis was required on the second day. The patient remainedcomplications related to recurrent thrombosis of her vascular
oliguric and was dialyzed every other day. On the seventh post-access. At the time of her transplant, she was being dialyzed
operative day, cyclosporine (Neoral), 4 mg/kg twice daily, andvia a graft in her left thigh, and she was receiving therapy with
mycophenolate mofetil, 1500 mg twice daily, were started. Trans-low-dose warfarin. Anticardiolipin antibodies were negative.
plant biopsy, scheduled for postoperative day 10, was cancelledA cadaveric kidney became available for her two years ago.
when her urine output began to increase steadily. The lastThe kidney was from a 22-year-old victim of a gunshot wound
dialysis was on the 10th postoperative day, and the patient wasand was mismatched at four human leukocyte antigen (HLA)
discharged from the hospital two days later. Her medications
at the time of discharge are shown in Table 1, column 1.
The patient was followed in the renal transplant outpatientKey words: acute rejection, tacrolimus, mycophenolate mofetil, basilix-
clinic every two to three days. Her renal function began toimab, daclizumab, sirolimus, CD25 receptor, cyclosporine.
improve, and no further dialysis was required. By postoperative
The Nephrology Forum is funded in part by grants from Amgen, day 24, her serum creatinine had fallen to 3.8 mg/dL but then
Incorporated; Merck & Co., Incorporated; AstraZeneca LP; Dialysis rose to 4.2 mg/dL. Renal ultrasound was unremarkable. A
Clinic, Incorporated; and R & D Laboratories. transplant biopsy showed findings consistent with healing acute
tubular necrosis, tubulitis consistent with a Banff grade-II acuteÓ 2001 by the International Society of Nephrology
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Table 1. Post-transplant medication regimen
Postoperative day
Drug 12 42 360
Cyclosporine 200 mg bid 150 mg bid 125 mg bid
MMF 1500 mg bid 1500 mg bid 1000 mg bid
Prednisone 40 mg bid 15 mg qd 7.5 mg qd
Ganciclovir 1000 mg bid 1000 mg tid —
TMP-SMX Ss qd Ss qd —
Nystatin tid — —
Atorvastatin 20 mg qd 20 mg qd 20 mg qd
Diltiazem CD 180 mg qd 180 mg qd 180 mg qd
Clonidine 0.2 mg tid — —
Enalapril — 5 mg qd 10 mg qd
Abbreviations are: MMF, mycophenolate mofetil; TMP-SMX, trimethoprim-
sulfamethoxazole; qd, once daily; bid, twice daily; tid, thrice daily; Ss, single
strength.
fibrosis and tubular atrophy. The patient’s medications at that
time are shown in Table 1, column 3.
DISCUSSION
Dr. Gabriel M. Danovitch (Medical Director, Kidney
Transplant Program, Division of Nephrology; and Pro-
fessor of Medicine, UCLA School of Medicine, Los Angeles,
California, USA): This patient illustrates many of the
“multiple choice questions” faced by transplant programs
as they attempt to take advantage of the expanding arma-
mentarium of immunosuppressive medications at their
disposal. Moreover, difficult choices commonly have to
be made, as in this case, about whether to accept an
organ, the functional quality of which was less than ideal.
Fig. 1. Donor kidney biopsy obtained at the time of harvesting, stained Should this particular kidney have been offered to her?
with Masson’s trichrome. (A) Foci of tubular atrophy and interstitial On what basis was the decision made to choose herfibrosis (arrows) involve 20% of the renal parenchyma (350). (B)
immunosuppressive protocol? How can we best protectMarked arteriolar hyalinization (arrowhead) with an adjacent glomeru-
lus showing mild ischemia and atrophic tubules with associated intersti- her from the life–threatening complications that are a
tial fibrosis (3200). potential consequence of intensive immunosuppression?
What can be done to maximize the functional life of her
transplant after she had spent half a lifetime with end-
stage renal disease? This Forum will attempt to answerrejection, and vascular changes thought to be of donor origin.
these questions or, at the very least, provide a rationalShe received daily infusions of 5 mg/kg methylprednisolone
for three days; her oral prednisone dose was rapidly tapered basis for addressing them.
to 20 mg daily. Her serum creatinine fell to 2.2 mg/dL at six To understand the design of the immunosuppressive
weeks post transplant. Her medications at that time are shown protocol, one must not only be familiar with the medica-
in Table 1, column 2. tions per se, but also with the evolution of their introduc-
Over the ensuing year, the patient was seen regularly at the
tion into clinical transplantation. In the 1960s and 1970s,transplant clinic. She felt good and returned to work. Her course
utilization of corticosteroids, azathioprine, and the earlywas complicated by an episode of graft dysfunction ascribed to
polyclonal antilymphocytic agents was based largely oncyclosporine toxicity, a urinary tract infection with E. coli treated
with ciprofloxacin, and a three-day hospital admission for an individual center experience without rigorous multicen-
episode of bacterial pneumonia treated empirically with azithro- ter trials or predetermined end-points [1]. In the last two
mycin. She gained an additional 8 kg in weight. Blood pressure decades, all the new immunosuppressive agents have been
was 130/90 mm Hg. Total serum cholesterol was 190 mg/dL introduced after clinical trials. The design of these trials
with a low-density fraction of 120 mg/dL. At the end of the
and the end-points used to assess efficacy have had a majorfirst post-transplant year, the serum creatinine fluctuated be-
influence on the way in which the new agents are used.tween 2.2 and 2.5 mg/dL, and a 24-hour urine collection con-
When the first clinical trials for cyclosporine were de-tained 2.5 g of protein. A transplant biopsy showed evidence
of chronic transplant glomerulopathy with patchy interstitial signed in the late 1970s and early 1980s, the primary end-
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point used was “improvement of patient and graft sur- safely reduce the incidence of episodes of acute rejection
thus has become the major yardstick by which new agentsvival,” which cyclosporine indeed achieved [2]. The re-
sults of renal transplantation were relatively poor at that are assessed. It therefore behooves us to understand the
implications and rationale for choosing this particulartime, so it was not hard to recognize the dramatic benefit
of cyclosporine, which produced statistically significant end-point.
improvement in patient survival and permitted graft sur-
Incidence of acute rejection episodes as an end-pointvival rates of greater than 80% at one year. In Europe
for studies of new immunosuppressive drugscyclosporine was often used alone, while in the United
States it was usually combined with prednisone and aza- The incidence of acute rejection episodes, typically
“biopsy-proven,” has become the most frequently usedthioprine. Azathioprine was regarded as an adjunctive
agent to cyclosporine and the combination was often marker of the effectiveness of new immunosuppressive
drugs for the following reasons:called “triple therapy.” Although the benefits of cyclo-
sporine were clear cut, its capacity to produce both acute (1) The excellent results of renal transplantation using
currently available immunosuppressive agents, which yieldand chronic nephrotoxicity was soon recognized to be a
major “thorn in its side” [3]. In 1985, OKT3, the first a one-year graft survival of close to 90% and minimal
mortality in most centers, make it extremely difficult tomonoclonal antibody used in clinical medicine, was intro-
duced into routine clinical care based on its capacity to use patient or graft survival as markers to prove statisti-
cally significant benefit from the use of a new agent.successfully treat first acute rejection episodes [4]. But
the toxicity of the drug tended to restrict its use to epi- (2) Acute rejection is a potent risk factor for the devel-
opment of chronic allograft failure. In retrospective anal-sodes of rejection that were resistant to high-dose ste-
roids and, in some programs, to its use for the induction yses, patients who have suffered episodes of acute rejec-
tion have a long-term graft survival of 20% to 45% lessof immunosuppression as an alternative to polyclonal
antibody preparations. With these medications—cyclo- than patients who have not [13].
(3) Acute rejection episodes are morbid events insporine, azathioprine, corticosteroids, and the antibody
preparations—the transplant community entered the 1990s themselves, requiring intensification of immunosuppres-
sion and sometimes hospital admission.achieving, with justifiable pride, success rates of up to
90% and minimal mortality in many centers. The number (4) Most acute rejection episodes take place within
the first few months of transplantation, and their pres-of available immunosuppressive medications was small,
so relatively little variation existed among the protocols ence can be proven by biopsy [14]. This pathophysiologic
sequel permits rapid evaluation of the effectiveness ofused in different programs.
Major developments occurred in the 1990s. Tacroli- a new agent or protocol (a luxury not available when
immunosuppressive drug trials are performed in othermus (FK506) was introduced into liver transplantation
and eventually into renal transplantation as an alterna- clinical circumstances, such as in systemic lupus erythe-
matosus, rheumatoid arthritis, etc.).tive to cyclosporine because of its ability, proven in ran-
domized clinical trials, to produce equivalent patient and As an example of this approach for evaluating the
effectiveness of new immunosuppressive agents, Figure 2graft survival [5]. Mycophenolate mofetil (MMF) was
found to be a more effective adjunctive agent than aza- contains data from one of the pivotal trials leading to the
introduction of MMF [6]. This trial was a randomized,thioprine by virtue of its capacity to reduce the incidence
of acute rejection episodes when used with cyclosporine double-blind, placebo-controlled, multicenter, phase-III
study to evaluate the efficacy of MMF in the prevention[6], and later with tacrolimus [7], and corticosteroids.
Two new humanized monoclonal antibodies, basiliximab of acute rejection episodes during the first six months
following renal transplantation. In this trial, standardand daclizumab, both targeted against the interleukin-2
(CD25) receptor, were approved for use in renal trans- therapy consisted of cyclosporine, prednisone, and aza-
thioprine. The study compared two doses of MMF (1.0 gplantation in 1998, again because of their ability to re-
duce the incidence of acute rejection episodes [8, 9]. twice daily and 1.5 g twice daily) or azathioprine in com-
bination with cyclosporine and prednisone. In the UnitedThymoglobulin, a polyclonal antibody available in Eu-
rope for several years, was approved for use in the US States, the study involved 500 recipients of a first cadav-
eric transplant (very similar studies involving anotherfor the treatment of acute rejection [10]. In late 1999,
sirolimus (rapamicin) was added to the immunosuppres- 1000 patients were performed in Europe, Canada, and
Australia). Figure 2A illustrates the clear-cut benefit ofsive menu, again because when combined with cyclospor-
ine and corticosteroids, it reduced the incidence of acute MMF with respect to the primary end-point: a statisti-
cally significant reduction in the incidence of acute rejec-rejection episodes [11, 12]. Several new agents also are
being evaluated in a similar fashion, that is, by their tion episodes, from nearly 50% in the azathioprine group
to approximately 25% in both the MMF groups. Theability to reduce the incidence of acute rejection epi-
sodes. The ability of a new immunosuppressive agent to use of high-dose steroids and OKT3 also was markedly
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Fig. 2. Impact of mycophenolate mofetil
(MMF) on incidence of acute rejection and
graft survival. (A) Cumulative incidence of
acute rejection episodes within the first six
post-transplant months. (Reprinted with per-
mission from Transplantation [6]). Symbols
are: (m) azathioprine group; (s) MMF 2.0 g
daily; (d) MMF 3.0 g daily. (B) Three-year
follow-up of graft survival from the same
study. (Reprinted with permission from the
American Journal of Kidney Disease [15]).
reduced in the MMF groups. However, this study, which “standard therapy” with cyclosporine and prednisone
(typically combined with azathioprine in the US andhad a major impact on the way immunosuppression is
practiced, did not demonstrate a statistically significant placebo in Europe). The success of MMF in reducing
the incidence of acute rejection led to it becoming partbenefit of MMF with respect to patient or graft survival
when estimated at either one or three years [15] (Fig. 2B). of an updated standard therapy protocol in many centers.
In future trials of newer agents, MMF, or possibly siroli-Pivotal clinical trials led to the introduction of MMF,
sirolimus, and the anti-CD25 monoclonal antibodies in mus, will represent standard therapy, and statistical proof
of further reduction in the incidence of acute rejectionclinical transplantation (Table 2). A statistically signifi-
cant reduction in the incidence of acute rejection epi- will likely be more difficult to achieve. Similarly, it is
becoming more difficult to introduce new drugs basedsodes within the first six post-transplant months was
achieved for each of these drugs. However, on prospec- on their capacity to reverse episodes of acute rejection,
as these episodes have become less frequent.tive analysis, neither patient nor graft survival was statis-
tically significantly improved in any of these studies, ei- Although researchers have been unable to demon-
strate statistically significant improvement in long-termther on short- or long-term follow-up.
As new immunosuppressive drugs and protocols are graft survival in prospective analyses of the new genera-
tion of immunosuppressive agents, evidence emergingintroduced and the incidence of acute rejection falls, it
has become increasingly difficult to prove the statistically from large transplant registries indicates that the half-life
of cadaveric kidneys is improving [16]. This discrepancysignificant benefit of even newer agents. In the pivotal
trials leading to the introduction of MMF, sirolimus, and could reflect the lack of statistical power of the smaller
prospective studies in proving the significance of smallthe anti-CD25 monoclonal antibodies [6, 8, 9, 11], the
incidence of acute rejection in the patients receiving the differences in graft survival. For example, if a new drug
or protocol reduces the incidence of acute rejection epi-experimental drug protocol was compared to the inci-
dence of acute rejection in patients receiving so-called sodes by 20%, and patients who suffer an episode of
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Table 3. Components of the immunosuppressive protocolTable 2. Incidence of biopsy-proven acute rejection episodes from
selected randomized clinical trials using standard dose of
Class of agent Optionsexperimental agent
Calcineurin inhibitor Cyclosporine, tacrolimusAgents compared % Acute rejection
Corticosteroids Dose and regimen
Adjunctive agent Azathioprine, MMF, sirolimusControl Experimental Control Experimental Reference
Antibody induction OKT3, ATGAM, thymoglobin
CsA, Aza FK, Aza 6 31 5 Anti-CD25 monoclonal antibody Basiliximab, daclizumab
CsA, Aza CsA, MMF (2 g) 41 20 6 Supplementary agents CCB, HCRI
FK, Aza FK, MMF (2 g) 44 27 7 Infection prophylaxis TMP-SMX, antivirals
CsA CsA, basiliximab 48 33 8
Abbreviations are: MMF, mycophenolate mofetil; CCB, calcium channelCsA, Aza CsA, daclizumab 43 27 9
blocker; HCRI, HMG CoA reductase inhibitor; TMP-SMX, trimethoprim-sulfa-CsA, Aza CsA, rapa (2 mg) 24 15 12
methoxazole.
Abbreviations are: CsA, cyclosporine; Aza, azathioprine; FK, tacrolimus;
MMF, mycophenolate mofetil; rapa, sirolimus. All trials included standard dos-
age of corticosteroids. From Ref. 12.
which often have been developed in response to local
experience. The components of a standard immunosup-
acute rejection have a 25% increased chance of graft pressive protocol (Table 3) are relevant to all recipients,
loss at three years post transplantation, then the potential with the possible exception of two-haplotype-matched
impact of the drug or protocol on three-year graft sur- living related donors [21]. Since the risk of acute rejection
vival would be only 5%. Several thousand patients would is highest in the first weeks and months after transplanta-
need to be followed for three years for the study to have tion (induction phase) and diminishes thereafter (main-
the statistical power to prove this difference, and such tenance phase), immunosuppression is at its highest level
prospective studies are logistically impractical. Hun- in this early period and is reduced for long-term therapy.
sicker and Bennett have estimated that to detect with The most feared side effects of immunosuppression—
80% power a 30% reduction in late graft loss, a five- opportunistic infection and malignancy—tend to reflect
year follow-up of 1500 patients would be required; they the total amount of immunosuppression given rather than
described this phenomenon as the “price of success” [17]. the dosage of a single drug. The availability of multiple
Registry data permit retrospective evaluation of many potent immunosuppressive agents might tempt practi-
thousands of patients and are not constrained by the tioners into a potentially dangerous polypharmacy. The
necessity for prospective follow-up of individual patients. benefit of the new agents in terms of their capacity to
In a retrospective analysis of approximately 8,500 renal reduce the incidence of acute rejection episodes should
transplant recipients who received MMF with cyclospor- be weighed against their cost, both economic and clinical.
ine and corticosteroids between 1992 and 1997, Ojo et The total quantity of immunosuppression should be mon-
al reported that the risk of chronic allograft failure was itored and considered in all stages of the post-transplant
course.reduced by 27% compared with those patients who re-
Cyclosporine or tacrolimus? One or the other of theseceived azathioprine with cyclosporine and corticoste-
two drugs currently comprises the backbone of transplantroids. This effect appeared to be independent of the
immunosuppression. Although much has been made ofimpact of MMF on the incidence of acute rejection [18].
some distinct differences between cyclosporine and ta-It is also possible that the improvement in long-term
crolimus, the fact is that they are remarkably similar,graft survival is not related to the introduction of new
and both are highly effective [22]. Both drugs exert theirimmunosuppressive agents but is due to other factors
action by inhibiting the cytosolic phosphatase enzymesuch as better clinical care, better treatment of hyperten-
calcineurin, thereby preventing the passage through thesion, more effective infection prophylaxis, and increased
nuclear membrane of activating factors for critical cyto-use of HLA-matched cadaveric donors [19]. The fact
kine genes, particularly interleukin-2 [23]. The nephro-that registry data show improvement is all the more
toxicity of both drugs has been well documented and can-remarkable at a time when the overall quality of the
not be differentiated pathologically. Transforming growthcadaveric donor pool is steadily deteriorating (as re-
factor (TGF-b1) might play a major role in their acuteflected by increased donorage, incidence of hyperten-
and chronic nephrotoxic effects and on their impact onsion, and non-traumatic cause of death) [15, 20].
the natural history of malignant tumors [24, 25]. Trans-
General principles of immunosuppressive plant registry data show no significant difference in long-
protocol design term graft survival for patients taking cyclosporine or
tacrolimus [26], so the choice between them is basedThe variety of immunosuppressive drugs now avail-
able for use in clinical transplantation permit consider- largely on the profile of their side effects (Table 4). For
example, tacrolimus is more toxic to pancreatic isletsable permutations in immunosuppressive protocols. Trans-
plant centers tend to be loyal to their own protocols, than is cyclosporine, and this effect is manifest clinically,
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Table 5. Antibody preparations for renal transplantTable 4. Comparative side effect profile of cyclosporine
and tacrolimusa immunosuppression
IndicationCyclosporine Tacrolimus
Induction RejectionDrug interactions Similar Similar
Nephrotoxicity 1 1
MonoclonalHypertension and
OKT3 (1) 1sodium retention 1 1 1
Basiliximab 1* 2Pancreatic islet toxic 1 1 1
Daclizumab 1* 2Neurotoxicity 1 1 1
PolyclonalCosmetic side effects 1 1 1
ATGAM 1 1GI side effects 2 1
Thymoglobulin (1) 1Hyperkalemia 1 1
Hypomagnesemia 1 1 Symbols are: 1, approved indication; (1), unapproved but commonly used
indication; 1*, concomitant administration of calcineurin inhibitor recommended;Hypercholesterolemia 1 2
(2), not indicated.Cost Similar Similar
Signs are: (1) known effect; (1 1) effect more pronounced; (2) no or little
effect.
a Summarized from [21, 22, 27, 35, 48]
a protein, target-of-rapamicin (TOR), which plays a piv-
otal role in cell cycling, and does not inhibit calcineurin
[29]. It is unclear at this time to what extent transplant
particularly in African American patients [5]. Cyclospor- programs will prescribe sirolimus as a replacement for
ine therefore might be the better choice in some centers MMF. Both sirolimus and MMF were licensed based on
where the population of African American patients is their use in combination with cyclosporine and predni-
large because of the increased incidence of post-trans- sone. Post-licensing studies have shown that MMF, ta-
plant glucose intolerance in patients who receive tacroli- crolimus, and prednisone comprise an effective combina-
mus. Tacrolimus might be preferred in adolescent and tion [7]. It was originally believed that sirolimus and
other “cosmetically concerned” patients because of the tacrolimus should not be used together, as they occupy
more marked cosmetic changes associated with cyclo- the same receptor (FK-binding protein); preliminary
sporine [21]. Cyclosporine might be more suitable in studies suggest that this combination is acceptable and
some patients because of the generally milder neurologic effective because the receptor is not fully occupied even
side effects [22]. Tacrolimus might be the preferred when both are used [30]. Although sirolimus and MMF
choice in recipients of simultaneous kidney and pancreas have not been compared directly, sirolimus is probably
transplants because of its somewhat greater immunosup- a more potent immunosuppressant and its side effect
pressive potency despite its greater islet toxicity [27]. In profile differs from that of MMF. In particular, sirolimus
the United States, approximately 70% of renal trans- might have an unfavorable impact on the lipid profile,
plantation programs base their immunosuppression pro- and MMF might produce troubling gastrointestinal side
tocols on cyclosporine and the remainder on tacrolimus. effects [6, 11]. Both drugs can suppress the production
Which adjunctive agent? In this discussion I use the of formed blood elements to a degree comparable to
term “adjunctive agent” to describe the immunosuppres- azathioprine [21].
sive drugs that are used, or were developed for use, in Antibody induction. A variety of antibody prepara-
combination with a calcineurin inhibitor to enhance the tions are available for use in clinical transplantation,
potency of the immunosuppressive protocol, as measured either for the treatment of acute rejection episodes or,
by a decreased incidence of acute rejection episodes. in the early post-transplant phase, for the induction of
Most programs in the United States use an adjunctive immunosuppression (Table 5). Antibody induction ther-
agent for prophylactic purposes starting from the imme- apy generally refers to the use of OKT3 or a polyclonal
diate post-transplant period; some programs choose to antibody (ATGAM or thymoglobulin) in the first 7 to
introduce adjunctive therapy only in the event of an 14 days after transplantation. The calcineurin inhibitor
acute rejection episode. Azathioprine has been replaced is withheld, or its dose is kept to a minimum until 2 to 3
by MMF in most centers because of its superior ability days before the antibody course is completed. Induction
to reduce the incidence of acute rejection (Fig. 1A and protocols using OKT3 or a polyclonal antibody represent
Table 2) [6]. Azathioprine and MMF are both antimetab- an alternative to the use of a calcineurin inhibitor in
olites and inhibit purine metabolism, but MMF does so the early post-transplant period. When the anti-CD25
in a more selective fashion through inhibition of the monoclonal antibody preparations are used, concomi-
enzyme inosine monophosphate dehydrogenase [28]. tant use of a calcineurin inhibitor is recommended [8, 9].
Sirolimus became available for clinical use in late 1999. In so-called “sequential therapy,” OKT3 or the poly-
It is biochemically similar to tacrolimus and occupies the clonal antibody is administered and the calcineurin in-
hibitor is introduced only when renal function has fallensame receptor, but its mode of action is unique. It targets
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to a specified level (for example, a plasma creatinine with the calcineurin inhibitors for clearance by the P450
enzyme system, resulting in higher drug levels and per-of 3 mg/dL). The antibody is discontinued as soon as
adequate calcineurin inhibitor levels are achieved. A mitting administration of a lower dose [40]. Calcium-
channel blockers also might have some intrinsic immuno-patient with a graft that functions well thus might receive
only a few days of antibody treatment. modulatory activity of their own that is related to the
role of cytosolic calcium levels on gene activation [35].Evaluation of data from the large transplant registries
has shown no long-term graft survival benefit of antibody The routine inclusion of calcium-channel blockers in the
post-transplantation protocol has been reported to im-induction in the majority of patients [31]. Patients at high
immunologic risk, African American patients, children, prove one-year graft survival by 5% to 10% [41].
The HMGCoA reductase inhibitors (HCRIs) haveand patients with delayed graft function might benefit
from their use [32–34]. Antibody induction also might been shown to safely lower cholesterol levels and reduce
the incidence of clinically severe rejection in cardiacbe indicated for patients requiring anticonvulsant drugs,
which can make achieving therapeutic levels of calci- transplant recipients [42]. A similar beneficial effect has
been observed in a preliminary study in renal transplantneurin inhibitors difficult in the early post-transplant pe-
riod [35]. Use of the polyclonal preparations obviates recipients [43]. The mechanism of this effect might be
related to the ability of HCRIs to suppress the cytotoxicthe first-dose side effects of OKT3; however, OKT3 is
easier to administer [35] and is somewhat cheaper (,$600 activity of natural killer cells [43]. Also, HCRIs might
be important in the long-term post-transplantation regi-per dose compared to $800 per dose for the polyclonals).
In the doses typically administered, thymogobulin is prob- men by virtue of their capacity to reduce the cardiovascu-
lar risk, the major source of morbidity and mortalityably a more effective polyclonal agent than ATGAM [10]
and evidence suggests that its administration immedi- after transplantation [44].
The prevention of infection remains a critically impor-ately prior to transplantation reduces the incidence of
delayed graft function, possibly by reducing the expres- tant part of modern immunosuppressive protocols [37].
A full review of this topic is beyond the scope of thission of adhesion molecules [36]. The use of OKT3 or
the polyclonal antibodies is associated with a small but discussion. The benefit of the new agents and protocols
in terms of patient mortality and long-term graft survivalfinite increase in the incidence of post-transplant malig-
nancy and opportunistic infection; this risk increases if is small, so any measurable increase in opportunistic
infections and malignancy must be treated with greatuse of these drugs is prolonged or repeated [35–38].
The availability of MMF and the anti-CD25 monoclonal concern. The danger can be illustrated by two examples:
the high incidence of Epstein-Barr virus–related lympho-antibodies has reduced the use of OKT3 and the poly-
clonal antibodies at most centers. The two available anti- proliferative disorders in pediatric recipients of liver
transplants immunosuppressed with tacrolimus [45], andCD25 monoclonal antibodies, daclizumab and basiliximab,
are very similar. From the therapeutic standpoint, they an outbreak of fatal Pneumocystis carinii infection in the
phase-II trials of sirolimus at centers that were not usingboth have the capacity to reduce the incidence of acute
rejection episodes by approximately 15% compared to pla- routine prophylaxis [46]. Ganciclovir and trimethoprim-
sulfamethoxasole remain the “unsung heroes” of trans-cebo (Table 2), and they are both remarkably free of side
effects [8, 9]. The approved dosage regimen for basi- plant immunosuppression.
liximab (two doses of 20 mg at postoperative day 0 and
Immunosuppressive drug avoidance and withdrawal4) is more convenient than that for daclizumab (1 mg/kg
on postoperative day 0 and at two-week intervals for The availability of multiple effective immunosuppres-
sive agents has stimulated attempts at minimizing ora total of five doses); however, a shortened course of
daclizumab appears also to be effective. In the absence avoiding the most toxic components of the standard pro-
tocol. The most obvious targets for such efforts are corti-of side effects, the decision to use these agents is based
on each center’s assessment of their benefit, that is, the costeroids and the calcineurin inhibitors.
Steroid withdrawal, the discontinuation of steroid ad-effectiveness in reducing the incidence of acute rejection,
compared to their cost, approximately $1000 per dose. ministration post-transplantation, needs to be differenti-
ated from steroid avoidance, in which steroids are admin-The anti-CD25 monoclonal antibodies are not indicated
for the treatment of established acute rejection. istered only in the event of rejection. Steroid avoidance
has never been popular in the United States, although itSupplementary agents. The inclusion of calcium-chan-
nel blockers, usually either diltiazem or verapamil, in has been applied in Europe [47]. Steroid withdrawal is
currently being re-evaluated in a multicenter trial in thethe standard immunosuppressive regimen has several
potential advantages. In addition to their antihyperten- US using a cyclosporine- and sirolimus-based protocol.
Steroid withdrawal is a tempting approach in selectedsive properties, both drugs reduce calcineurin inhibitor-
induced vasoconstriction and protect against ischemic patients, although the anxiety associated with withdrawal
(both for the patients and their physicians!) has limitedgraft injury and nephrotoxicity [39]. Both drugs compete
Nephrology Forum: Immunosuppression for transplantation 395
its popularity. A randomized, blinded trial of steroid with- Individualization of immunosuppressive protocols
drawal at four months post-transplantation was per- All patients are not equal with respect to the chances
formed in a group of patients with good graft function, of rejection, graft loss, and development of drug-induced
who had not suffered rejection episodes, and who were side effects, and protocols should take this into account.
receiving cyclosporine and MMF in standard doses (ab- Patients who have received more than one transplant
stract; Matas et al, Transplantation 6:269, 1999). The trial and patients with high levels of preformed antibodies
was discontinued because of a 20% incidence of acute can require more intense therapy [21, 35]. Young pa-
rejection in the group in whom the steroid was with- tients tend to be immunologically aggressive and might
drawn, compared to a 5% incidence in the control group. benefit from routine antibody induction [34]. Older pa-
Most of the rejection episodes occurred in African Ameri- tients have decreased tolerance for potent immunosup-
can patients. Steroid withdrawal thus should be consid- pression [53].
ered only in patients who are at least several months The role of race in the success of renal transplantation
post-transplant, have not suffered recent or recurrent has been the subject of considerable debate and investi-
rejections, and have excellent graft function [48, 49]. gation. In the clinical trials leading to the introduction
African American patients might not be suitable candi- of tacrolimus, MMF, and sirolimus, African American
dates for withdrawal and all patients should be warned patients have required higher doses of immunosuppres-
of a small but finite increased incidence of rejection. A sive drugs to achieve the same immunosuppressive bene-
clear-cut benefit of withdrawal, in terms of certain ste- fit as did whites [5, 46, 54], and some programs routinely
roid-related side effects (for example, bone disease, hy- take this into account in protocol design [21, 33, 35]. As
perlipidemia) has not been demonstrated, presumably I said, African American patients are more likely to
because most of the familiar steroid-related problems suffer acute rejection when steroids are withdrawn. In
are produced by the high doses used in the early post- the US, allograft survival in African American recipients
transplant period [48]. Several studies have suggested tends to be approximately 10% to 20% less than that
that steroid-withdrawn patients might be subject to long- for white recipients whether the transplant was from a
term deterioration in graft function, so enthusiastic re- living or cadaveric donor [19, 55]. Several factors have
ports of successful withdrawal should be evaluated with been proposed to explain the lower survival, including
care [47–49]. noncompliance and socioeconomic factors [55], the preva-
In the pivotal trials leading to the introduction of lence of hypertension in blacks [56], evidence of stronger
cyclosporine, tacrolimus, MMF, and sirolimus, the drugs immune responsiveness [57], and faster metabolism of
were continued over the long term, and the safety of their immunosuppressive medications [58].
discontinuation was not studied in a rigorous fashion. It All donor kidneys are not equal with respect to their
might be possible to withdraw these drugs in some stable susceptibility to the immune or non-immune injury. Re-
patients [50] or to reduce their dose. Randomized trials cipients of living related transplants, particularly from
are in progress to provide a definitive answer to the two-haplotype-matched donors, might require less im-
safety of this approach. Trials also are in progress using munosuppression [21, 35] and these kidneys are more
low doses that target lower blood levels of the calcineurin likely to function well over the long term. On the con-
inhibitors in various combinations with MMF, sirolimus, trary, kidneys that suffer delayed graft function are more
and the anti-CD25 monoclonal antibodies. The potential susceptible to acute rejection and to chronic allograft
advantage of these protocols is that they could maintain failure [35, 59], particularly when mismatched for HLA
immunologic effectiveness while minimizing short- and [60]; the same is true for kidneys if early function im-
long-term nephrotoxicity. Large multicenter European proves only slowly [61]. Delayed graft function also has
trials have evaluated protocols that do not use calci- been shown to be a risk factor for long-term patient mor-
neurin inhibitors, replacing them with sirolimus or a com- tality [62]. A variety of factors related to the donor, the
bination of sirolimus and MMF [51, 52]. When sirolimus cause of the donor’s death, and the circumstances of
was used alone, graft survival (,90%) and the incidence organ retrieval and transplantation predispose to ische-
of acute rejection (,50%) did not differ significantly mic injury, delayed graft function, and poorer long-term
between the patients who received a calcineurin inhibitor prognosis [35, 59].
and those who did not [51]. Renal function was better
Should the kidney have been offered to this patient?in the calcineurin inhibitor-free group. Until the long-
term results of these trials can be evaluated critically, The decision to transplant a kidney into this woman
one should carefully evaluate and review, together with should be considered in the overall context of her end-
the patient, the known risks and benefits of avoidance, stage renal disease and the difficult clinical dilemma re-
withdrawal, or radical dose reduction of steroids and sulting from her prolonged wait for a cadaveric kidney
and her access failure. She had no potential living donorscalcineurin inhibitors.
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because of the strong family history of renal disease because her African American race, her preformed cyto-
toxic antibodies, the donor’s age and cause of death,and hypertension. Two years ago, she had a positive
crossmatch to a poorly histocompatibility matched, but and the prolonged cold ischemia time resulting from the
organ’s transfer from the East Coast of the US to theotherwise excellent, cadaveric kidney and was in dire
need because of her access failure and preformed cyto- West put her at increased risk of delayed graft function
and early acute rejection [21, 32, 34, 59]. We chose OKT3toxic antibodies. The transplant team was then faced
with a difficult and irrevocable decision—should they rather than ATGAM because of its greater ease of ad-
ministration. Thymoglobulin was not available. The anti-offer her the kidney that became available four months
later? The kidney was a full histocompatibility match to CD25 monoclonal antibodies were not used since their
documented clinical benefit has been in a low-risk popu-her and the crossmatch was negative, but the organ had
several features that predisposed it to delayed graft func- lation [8, 9]. Cyclosporine was chosen as her calcineurin
inhibitor rather than tacrolimus, as she was deemed totion. There were several donor-related problems, includ-
ing advanced age, death by cerebrovascular accident, a be at particular risk of post-transplant diabetes mellitus
because of her African American race, obesity, and fam-history of hypertension, pre-harvesting acute renal dys-
function and a prolonged cold-ischemia time [16, 19, 20, ily history of diabetes [5, 70]. We chose MMF as the
adjunctive agent because it is more effective than azathio-35, 59]. These features appear to outweigh the benefits
of favorable histocompatibility matching [63, 64]. A his- prine [15]; sirolimus was not available. The dose of MMF
was 1500 mg twice daily rather than the standard 1000 mgtory of hypertension is now obtained in approximately
25% of all donors in the US; both hypertension and death twice daily because of evidence that African American
patients require the higher dose to achieve the sameby cerebrovascular accident in the donor predispose to
hypertension in the recipient [20, 65]. Hypertension is degree of reduction of risk of rejection as do non-African
American patients [15, 54]. She received a standard ta-an important factor in determining racial differences in
renal allograft survival [56]. pering dose of prednisone. We gave her ganciclovir intra-
venously and then orally as a form of “pre-emptive”The unfavorable histologic changes might have been
underestimated in the original pathology report; 16% of therapy to prevent cytomegalovirus (CMV) infection. She
was at high risk for CMV infection because we had ad-the glomeruli were sclerosed, and interstitial and vascu-
lar changes were present. The increased use of physiolog- ministered OKT3 and because of evidence of prior donor
and recipient CMV infection [36]. Bactrim (TMP-SMX)ically marginal donor kidneys has led to an increased
reliance on donor biopsies, taken at the time of organ and nystatin were used as prophylaxis against oral candi-
diasis, urinary tract infection, and P. carinii pneumonia.retrieval, as a guide to the advisability of transplanting
them, or even of transplanting both kidneys to a single Diltiazem was used as part of her antihypertensive regi-
men and to permit a lower dose of cyclosporine [39, 40].recipient [66–69]. These biopsies are often performed
outside of normal working hours, under intense time Its dose was fixed to avoid fluctuations in the cyclosporine
level. Atorvastatin was used both for its effect on lipidconstraints, with less than ideal tissue fixation and stain-
ing. Under these circumstances, the percentage of scle- levels and its potential immunologic benefit [42, 43].
Four weeks after receiving the transplant, the patientrosed glomeruli has become a convenient marker of organ
quality. Two groups have suggested that the determining was treated with high-dose corticosteroids for what was
probably a mild acute rejection episode in a backgroundfeature should be the presence of 15% or 20% glomeru-
losclerosis [66, 67], and Remuzzi et al favor a scoring system of resolving acute tubular necrosis and chronic histologic
changes. High-dose “pulse” corticosteroids remain thethat also includes interstitial and vascular changes [68]. A
multivariate analysis, however, has shown that donor first-line therapy for most episodes of mild rejection, and
antibody preparations usually are held in reserve forbiopsy information adds little to what is already known
from the donor’s age and circumstances of death [69]. recurrent episodes or first episodes that are severe, par-
ticularly if there is a component of vascular rejection [35].Despite the unfavorable features of the kidney that
became available, the significance of which were ex- The patient had received OKT3 for induction therapy; a
second course of an antibody preparation within the firstplained to her, the transplant team decided to offer her
the kidney because she desperately needed it and be- eight weeks after transplantation greatly increases the
risk of lymphoproliferative disease and should be avoidedcause it was difficult to predict whether a more favorable,
crossmatch-negative kidney would become available for if possible [38]. By three months after transplantation,
her infection prophylaxis had been discontinued, andher in the near future.
enalapril had been substituted for clonidine for blood
Choice of immunosuppression and management of pressure control. Angiotensin-converting-enzyme inhib-
today’s patient itors and angiotensin II antagonists are safe and well
tolerated in renal transplant patients [71]. Angiotensin IIImmunosuppression was commenced with antibody
induction using OKT3. Antibody induction was used receptor blockade can decrease the levels of TGF-b that
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have been implicated in the fibrogenesis that is a feature gans inexorably lengthens, great care will be required to
use the organs and drugs at our disposal wisely.of chronic allograft nephropathy [72].
By one year after transplantation, she had evidence
of chronic allograft failure. This term is now preferred
QUESTIONS AND ANSWERS
to the previous, loosely used “chronic rejection” because
Dr. Nicolaos E. Madias (Executive Academic Dean,of the contribution of both immune and non-immune
Tufts University School of Medicine, Boston, Massachu-factors to its pathogenesis [73]. Retrospective analyses
setts): Thank you, Dr. Danovitch, for a fine presentation.have convincingly shown that the acute rejection episode
You reviewed the issue of individualization of patientthat she suffered increased her risk of chronic allograft
protocols. Yet, as you indicated, most patients tend to befailure [13, 16]. The episode was made more likely by her
immunosuppressed in a very similar fashion. The result isdelayed graft function, and it occurred despite an immuno-
that we likely are over-immunosuppressing many pa-suppressive regimen of proven effectiveness. The unfa-
tients and are under-immunosuppressing others. Whyvorable donor factors that I mentioned conspired to fur-
have we not been more successful in this regard?ther impair the long-term graft function through a process
Dr. Danovitch: Indeed, the transplant field has beenthat has been likened to accelerated senescence [74].
more successful in developing new immunosuppressiveThe optimal management of chronic allograft failure
agents than in determining who should receive them.remains unclear, and it has proven exceptionally difficult
With the exception of fully HLA-matched sibling pairs,to design clinical trials that would define effective strate-
the available immunologic and histocompatibility mark-gies [17]. Intensification of immunosuppression is gener-
ers have not proved to be adequately predictive for indi-ally not effective and is potentially dangerous; increasing
vidual patients. So, for the moment, we are left with thethe dose of the calcineurin inhibitor is likely to exacer-
rather broad demographic parameters that I outlinedbate its nephrotoxicity [35, 75]. Single-center studies have
[21]. Hutchinson and colleagues reported that certainevaluated the strategy of adding MMF to the immunosup-
cytokine gene polymorphisms in transplant patients arepressive regimen while reducing the dose of cyclosporine.
associated with increased cytokine production and rejec-The results have been mixed [75–77]. Replacement of
tion risk [78]. Recognition of these polymorphisms even-the nephrotoxic calcineurin inhibitor with sirolimus is a
tually might permit more individualized therapy. An-tempting strategy that is yet to be tested systematically.
other way to approach immunosuppression is to startApplication of principles similar to those used for the
with a less aggressive protocol, such as by excludingmanagement of chronic renal failure in native kidneys
corticosteroids or the adjunctive agent, and only intensi-might be effective, and blood pressure control with ACE
fying immunosuppression in the event of an acute rejec-inhibitors or angiotensin II receptor blockers might slow
tion. This approach is more popular in Europe than inthe progression of allograft failure [71, 72]. Death of the
the United States. Concern about the impact of acutepatient accounts for more than 40% of all graft loss [44].
rejection on long-term function has led to the trend ofThe most common cause of late post-transplant death
using intensive immunosuppression in the early post-is cardiovascular disease [20, 44]. Today’s patient has
transplant period. We are then left, as I said, with decid-multiple risk factors for coronary artery disease and, in
ing which agents can be safely withdrawn and when. Wethe absence of studies directly addressing these factors
obviously need more data.in the transplant population, it would seem appropriate
Dr. Madias: Can available medications used in differ-to extrapolate from recommendations made to the gen-
ent combinations further improve the outcome of trans-eral population. Therefore, we aggressively try to control
plantation? Do you anticipate that a further reductionher lipid levels and blood pressure while encouraging
in the incidence of acute rejection will have a favorableweight loss and regular exercise [20]. Attention to ath-
impact on graft longevity?erosclerotic risk factors could be the most important
Dr. Danovitch: Many transplant programs are achiev-contribution to the improvement of the longevity of pa-
ing greater than 90% success, as measured by graft func-tients with successful renal transplants [44].
tion at one year. There will inevitably be occasional graftThe management dilemmas that have faced this pa-
loss due to technical or other complications. Therefore,tient and her caregivers are by no means unique. Al-
we are approaching the maximization of short-term re-though the immunosuppressive choices that were made
sults. The current challenge lies in improving long-termwere successful in permitting her to navigate the first
success. A further reduction in the incidence of acutepost-transplant year, the quality of the kidney that was
rejection might well be reflected in an improvement intransplanted might well come back to haunt her in the
long-term function, although I suspect that this improve-months and years ahead. No immunosuppressive regi-
ment will be relatively small and difficult to measure. Inmen, no matter how effective, is likely to permit a physio-
our enthusiasm to reduce the incidence of early acutelogically marginal kidney to function as well as one from
an “ideal” donor. As the waiting time for cadaveric or- rejection episodes by using potent immunosuppressive
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protocols, we must ensure that we do not engender mor- might have some degree of ischemia in the immediate
subcapsular zone.bid complications that will negate their benefit. Many of
the so-called “antigen-independent” causes of long-term Dr. Danovitch: At the behest of our nephropathology
colleagues, several of the immunosuppressive trials I re-graft loss are related to the quality of donor organs and
pre- and post-transplant recipient cardiovascular disease ferred to have included baseline and protocol biopsies;
in patients in clinical trials, this is certainly appropriate.[20, 74].
Dr. Alan Wilkinson (Division of Nephrology, UCLA It is not yet clear to what extent the information obtained
will affect routine clinical care. I am reluctant to recom-Medical Center): I suspect that some of the discrepancy
that you describe between the measurable impact of mend routine inclusion of additional procedures until
we know more. I should add that in clinical trials it hasacute rejection on long-term function in retrospective
analyses compared to the lack of measurable impact on sometimes proved difficult to persuade stable patients
to undergo a protocol biopsy, and the degree of enthusi-prospective analyses also might be due to the fact that
not all rejections are equal. In clinical trials, most rejec- asm of the treating physicians for the procedure also has
been variable. As a result, the statistical analysis of thetions are recognized early and treated quickly and there-
fore could have a lesser impact on long-term graft loss. biopsy data often has been incomplete [15].
Dr. Cohen: Could you comment on the finding ofDo you think that clinical trials accurately reflect routine
clinical experience? polyoma viral infection in transplant patients? One re-
cent report suggests that patients who receive tacrolimusDr. Danovitch: That is a good point. Indeed, it is
common for patients enrolled in clinical trials to do bet- are at much greater risk for developing this infection
[80]. Does this risk enter into your consideration forter than their non-trial counterparts even if they are in
the control group, presumably because of the intensity of selecting that drug versus cyclosporine? Why is polyoma
viral infection of the transplant so rarely encountered?clinical monitoring and the early histologic confirmation
and treatment of acute rejection. Fortunately, the clinical Dr. Danovitch: Human polyoma BK virus indeed has
become a more frequently recognized infectious agenttrials have had an impact on clinical management and
the tendency now in most transplant programs is to in immunosuppressed patients, but I suspect that it’s
been there all along, but missed. It presents clinically inbiopsy the transplant to confirm a clinical impression
of rejection rather than to treat a suspected rejection heavily immunosuppressed patients as a severe acute
rejection that appears unresponsive to further intensifi-empirically [59].
Dr. Michael Bunnapradist (Division of Nephrology, cation of immunosuppression, and the kidneys are usu-
ally lost [80]. It takes an astute pathologist like yourself toCedars Sinai/UCLA Medical Center): What is your opin-
ion of the role of the “protocol biopsy” in post-transplant suspect its presence. The biopsy specimens show severe
tubulointerstitial nephritis with large basophilic intra-immunosuppression management?
Dr. Danovitch: Dr. David Rush and colleagues have nuclear inclusions. Special staining with polyoma virus
monoclonal antibody confirms the diagnosis, and thepioneered the evaluation of the protocol biopsy in post-
transplant management [79]. In doing so, they proposed viral DNA can be identified in plasma. Most of the cases
have occurred in patients who have received tacrolimus,the concept of “sub-clinical” acute rejection, which is
defined by a usually mild lymphocytic infiltrate in the but the drug has typically been given for “rescue” after
the use of antibody preparations and other agents. Iabsence of an elevation in the serum creatinine level [55].
There is some question as to the pathologic significance doubt that the infection is specific for tacrolimus, and
consideration of this risk does not influence the choiceof these infiltrates, but treating them as rejections might
improve long-term graft function [79]. If this important of agent. Rather, this virus is a reminder to us that we
should always consider what our infectious disease col-observation can be confirmed, then the introduction of
a protocol biopsy into routine care certainly would be a leagues call “the net state of immunosuppression” [37]
and avoid excessive intensification of our regimens withrational way to guide immunosuppressive management.
Dr. Arthur Cohen (Department of Pathology, Cedars the potent agents now available.
Dr. Harry Ward (Division of Nephrology, King Drew/Sinai/UCLA Medical Center): A discussion of protocol
biopsies should include consideration of a baseline biopsy UCLA Medical Center): Irrespective of how well we are
doing with improved immunosuppressive protocols, weat the time of transplantation. This approach permits
identification of pre-transplant immunologic and non- are still faced with a serious shortage of cadaveric organs.
Considering the ratio of people awaiting organs to theimmunologic damage and the more accurate interpreta-
tion of biopsies performed after transplantation. The availability of donors, do you think that we will have
to ration cadaveric kidneys using some kind of broadlybaseline biopsy has to be performed by the surgeon cor-
rectly. It is not adequate to shave the immediate subcap- accepted criteria such as age, prior transplantation, or
expected longevity? Should we direct the marginal kid-sular zone of the kidney, which can be a very unrepresen-
tative part of the kidney, especially in older donors who neys to older patients or other high-risk groups?
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Dr. Danovitch: The question you raised is an inescap- Dr. Danovitch: In principle, all patients on chronic
dialysis or with irreversible end-stage renal diseaseable one, and the nephrology and transplant communi-
ties as well as the general public will need to come to should be regarded as potential transplant recipients.
When making decisions as to the appropriateness ofgrips with it in the years ahead. It will not be resolved
until xenotransplants become a clinical reality. Person- transplant candidacy for individual patients, we should
employ an evidence-based approach whenever possibleally, I am very reluctant to exclude, disadvantage, or
promote certain patient groups with respect to access and avoid making value judgments. Transplant programs
and nephrologists need to educate patients about theto transplantation, because all potential recipients can
benefit from it either in terms of improved mortality rates relative risks and benefits of transplantation to help them
make informed decisions. The American Society ofor quality of life [44]. I don’t have any easy solutions. I
do know that nobody wants to return to the kind of Transplantation has published guidelines for the evalua-
tion of transplant recipients. These guidelines will be“thumbs-up, thumbs-down” decision-making that was a
feature of the early days of hemodialysis. updated on a regular basis and address in a detailed
fashion the difficult issues to which you refer [81].Dr. Madias: Could you please comment on the avail-
able experience with dual grafting? Dr. Robert Ettenger (Department of Pediatrics,
UCLA Medical Center): Would you comment on theDr. Danovitch: I will ask my surgical colleague to
respond. contribution that noncompliance with medications might
make to the evolution of chronic graft dysfunction?Dr. H. Albin Gritsch (Department of Urology, UCLA
Medical Center): By dual grafting I presume you are Dr. Danovitch: You are certainly in order to bring
up the issue of noncompliance in a discussion of thereferring to the simultaneous use of both kidneys from
older “marginal donors.” The use of both kidneys from intricacies of transplant immunosuppression. In renal
transplantation, clinically important noncompliance haspediatric donors transplanted “en bloc” is also a form
of dual grafting. Both these maneuvers are a reflection of been reported in 15% to 20% of recipients, and it sub-
stantially increases the risk of adverse immunologicour attempts to maximally exploit the available cadaveric
donor pool. Marginal kidneys are sometimes discarded events and even death [82]. Several social and demo-
graphic variables appear to affect the likelihood of non-for fear they will not provide adequate renal function
for their recipients if they are used individually. Some compliance [83]. These include young age, psychiatric
illness, low socioeconomic status, financial hardship, andcenters now advocate the use of two kidneys from donors
over the age of 60 if the renal function is impaired or if a history of substance abuse. Noncompliance increases
the risk of graft loss by three- to fivefold and is a commonthe biopsy taken at the time of organ retrieval reveals
significant histologic damage [67]. One kidney can be cause of late graft loss [82].
The approach to noncompliance by the transplantplaced in each iliac fossa using a preperitoneal midline
incision or separate lower abdominal incisions. Alterna- community needs to proceed both on a national and
individual level. The financial strain on patients has beentively, both kidneys can be placed on one side, with
anastomosis of the vessels of one kidney to the common alleviated somewhat by the extension of Medicare cover-
age to 44 months, and the Institute of Medicine hasiliac artery and the vena cava. Early experience with
transplantation of double marginal kidneys suggests that recommended eliminating all time limits on Medicare
coverage of immunosuppressant medications. As always,results of graft survival and renal function are compara-
ble to that achieved with single kidneys from older do- the development and maintenance of a trusting relation-
ship between the patient and the caregiver is key tonors [67, 68]. Older recipients might benefit more with
kidneys from older donors, as their metabolic demands optimal outcome [82, 83].
Dr. David Lee (Division of Nephrology, Sepulvedacan be fewer. As yet, no nationally accepted guidelines
exist for determining whether one or both kidneys should Veterans Administration Hospital): You spoke of an in-
crease in live kidney donation in the United States. Werebe transplanted; the decision has been made by individ-
ual transplant centers. the donors related or non-related? Please comment on
the future, at least in the United States, of living non-Dr. Gerald Friedman (Nephrologist, Upland, Cali-
fornia): You discussed the problem of the shortage of related donation.
Dr. Danovitch: Most of the increase in living donationcadaveric organs and the deteriorating quality of the
cadaveric donor pool. What about the marginal recipi- in the United States has come as a result of donation from
people who are not biologically related. Non-related, orent? I have patients in my practice who have been illicit
drug users, patients who are noncompliant with therapy, the term I prefer “emotionally related” donors, now
account for approximately one-third of all living dona-and patients in their late sixties or older who end up
on the transplant list and who receive kidneys before tions. A major stimulus for this expansion came as a
result of the landmark report in 1995 by Terasaki andpotentially better-suited recipients. Should we be more
selective about the patients to whom we give organs? colleagues that the results of such donation approxi-
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cost information for immunosuppressive drugs was provided by themated the results of donation from the more traditional
UCLA Department of Pharmaceutical Services.biologically related sources [84]. Most of the biologically
unrelated donors are spouses, close or distant relatives, Reprint requests to Dr. G. Danovitch, Kidney and Pancreas Trans-
plant Programs, UCLA School of Medicine, 10833 Le Conte Avenue,close friends, or adopted family. Some programs accept
Box 95176, Los Angeles, California 90095-1796, USA.donors who have no personal relationship with the recip-
E-mail: gdanovitch@mednet.ucla.edu
ient, so-called “good Samaritan” or altruistic donors. I
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